| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 12,462 | 9,652 | 8,751 | 6,974 |
| Cost of product sales | 660 | 967 | 373 | 1,357 |
| Research and development | 29 | 107 | 94 | 97 |
| Selling and marketing | 5,210 | 4,354 | 2,947 | 4,601 |
| General and administrative | 6,752 | 6,956 | 6,145 | 6,121 |
| Total operating expenses | 12,651 | 12,384 | 9,559 | 12,176 |
| (loss)/income from operations | -189 | -2,732 | -808 | -5,202 |
| Debt securities, available-for-sale, unrealized loss | - | - | - | 3 |
| Unrealized foreign exchange gain/(loss) | -3 | 17 | 13 | - |
| Amortization expense | 12 | 13 | 13 | 21 |
| Interest income | 152 | 171 | 236 | 516 |
| Unrealized loss on securities | - | 1 | 1 | - |
| Interest expense | 586 | 594 | 592 | 1,025 |
| Total other expense | -449 | -420 | -357 | -533 |
| Net (loss)/income | -638 | -3,152 | -1,165 | -5,735 |
| Earnings per share, basic | -0.02 | -0.11 | -0.04 | -0.21 |
| Earnings per share, diluted | -0.02 | -0.11 | -0.04 | -0.21 |
| Weighted average number of shares outstanding, basic | 27,889,000 | 27,664,000 | 27,578,000 | 27,371,000 |
| Weighted average number of shares outstanding, diluted | 27,889,000 | 27,664,000 | 27,578,000 | 27,371,000 |
FENNEC PHARMACEUTICALS INC. (FENC)
FENNEC PHARMACEUTICALS INC. (FENC)